Drugs / BR9003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04857047 | Mar → Jun 2021 | — | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04846998 | Mar → May 2021 | — | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR9003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04857047 ↗ |
| Route | Oral | “Once-daily oral administration” NCT04846998 ↗ |